Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of treatment with triple therapy
an inhaler that contains three types of asthma medications, on participants with poorly
controlled asthma. The triple therapy medication contains fluticasone furoate, an inhaled
corticosteroid (ICS) which reduces inflammation in the lungs; umeclidinium (UMEC), a
long-acting muscarinic antagonist (LAMA), a medication which helps open up the airways; and
vilanterol (VI), a long-acting beta2-adrenergic agonist (LABA) which also helps open up
airways, delivered in a single daily inhalation via an Ellipta inhaler. The Investigators
will evaluate lung structure and function using magnetic resonance imaging (MRI).
Participants will inhale xenon gas before an MRI image of their lungs is taken. Using a
special technique xenon is visible in MRI images, so this lets us see how air spreads in the
lungs. In healthy lungs, the gas fills the lungs evenly, but in unhealthy lungs, the gas may
fill the lungs unevenly and they will appear patchy. The patchy areas are called ventilation
defects. A CT of the chest will be done to assess the structure of the lungs. The
Investigators will also be using lung function testing and questionnaires to compare them to
MRI ventilation defect measurements.